CLDN1 Cancer Research Results

CLDN1, claudin-1: Click to Expand ⟱
Source:
Type: gene
The CLDN1 gene (Claudin-1) is a tight junction protein that plays a crucial role in maintaining epithelial barrier function and regulating cell-cell adhesion.

Breast cancer: Elevated in 50% of breast cancer, associated with poor prognosis
Lung cancer: Elevated in 60% of lung cancer tissues, associated with poor prognosis
Colorectal cancer: Elevated in 70%, associated with poor prognosis
Prostate cancer: REDUCED in 40%, and associated with poor prognosis
Ovarian cancer: Elevated in 55%, associated with poor prognosis
Gastric cancer:Elevated in 60%, associated with poor prognosis
Hepatocellular carcinoma:Elevated in 65%, associated with poor prognosis
Pancreatic cancer: Elevated in 75%, associated with poor prognosis


Scientific Papers found: Click to Expand⟱
5740- Buty,    A Review of Nutritional Regulation of Intestinal Butyrate Synthesis: Interactions Between Dietary Polysaccharides and Proteins
- Review, RCC, NA
*eff↓, excessive protein fermentation produces branched-chain fatty acid (BCFA), ammonia, phenols, and other metabolites that inhibit butyrate production
Dose↝, Several studies have found that the ratio of acetate to propionate to butyrate in the colon of healthy individuals (regardless of region) has been found to be approximately 60:20:20 [2,3].
eff↑, An appropriate polysaccharide-to-protein ratio appears crucial for maintaining gut microbial homeostasis and facilitating butyrate generation.
HDAC↓, butyrate is a classic HDAC inhibitor that increases the acetylation level of histone H3 and H4,
ac‑H3↓,
ac‑H4↓,
*HCAR2↑, butyrate is produced by the gut microbiota at high concentrations (10–20 mM) and acts as an endogenous agonist of GPR109A.
*Inflam↓, When butyrate activates GPR109A on colonocytes, it triggers intracellular signaling cascades, promotes the secretion of the anti-inflammatory cytokine IL-18,
*ROS↓, Moreover, butyrate reduces the level of reactive oxygen species by activating the Nrf2 antioxidant pathway and enhancing glutathione (GSH) synthesis, and alleviate stress damage to the to intestinal barrier and immune cells.
*NRF2↑,
*GSH↑,
*CLDN1↑, Butyrate also enhances epithelial barrier function by upregulating the expression of tight junction proteins such as Claudin-1, Occludin, and ZO-1 in intestinal epithelial cells.
*ZO-1↑,
IL1β↓, rucial role in repairing and strengthening the intestinal barrier by downregulating the transcription of pro-inflammatory genes, including IL-1β, IL-6, and COX-2,
IL6↓,
COX2↓,
eff↝, Different types of monosaccharides significantly influence the efficiency of butyrate production due to their distinct chemical properties and microbial utilization mechanisms.
eff↑, After entering the colon, polysaccharides serve as fermentation substrates for gut microbiota and are broken down into butyrate.
other↝, A central challenge in current research on gut microbiota and butyrate production lies in determining the optimal dietary ratio of polysaccharides to proteins.

5932- CAR,    Carvacrol attenuates mucosal barrier impairment and tumorigenesis by regulating gut microbiome
- in-vivo, IBD, NA - in-vivo, Park, NA
*GutMicro↑, Carvacrol can regulate the gut microbiota. bundance of specific microbiota, such as Lactobacillus, Escherichia coli/Shigella, and Lachnoclostridium.
Risk↓, Carvacrol inhibits the development of colitis-associated colorectal cancer.
*Inflam↓, nti-inflammatory and antioxidant traits,
*antiOx↓,
*ZO-1↑, carvacrol significantly restored colonic length (p < 0.01) and re-established key tight junction proteins like ZO-1.
*iNOS↓, downregulated mRNA levels of inflammatory mediators such as iNOS and IL-6.
*IL6↓,
*NO↓, carvacrol has been shown to suppress nitric oxide and prostaglandin E2 production
*PGE2↓,
*memory↑, carvacrol improves memory deficits in Parkinson’s disease models
*TLR4↓, anti-inflammatory effects of carvacrol by inhibiting the TLR4/NF-κB signaling pathway
*NF-kB↓,
*IBI↑, Carvacrol improves intestinal barrier function
*CLDN3↑, expression levels of ZO-1, Claudin3, Claudin1, Occludin, and Mucin were significantly increased in the carvacrol group compared to the DSS group
*CLDN1↑,
*MUC1↑,
*OCLN↑,
*iNOS↑, carvacrol significantly inhibited the mRNA expression levels of iNOS, COX-2, Interferon-γ, IL-1β, and IL-6 in the intestinal tracts of colitis mice
*COX2↓,
*IFN-γ↓,
IL1β↓,
ADAM10?,


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Transcription & Epigenetics

ac‑H3↓, 1,   ac‑H4↓, 1,   other↝, 1,  

Proliferation, Differentiation & Cell State

HDAC↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   IL1β↓, 2,   IL6↓, 1,  

Synaptic & Neurotransmission

ADAM10?, 1,  

Drug Metabolism & Resistance

Dose↝, 1,   eff↑, 2,   eff↝, 1,  

Clinical Biomarkers

IL6↓, 1,  

Functional Outcomes

Risk↓, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↓, 1,   GSH↑, 1,   NRF2↑, 1,   ROS↓, 1,  

Cell Death

iNOS↓, 1,   iNOS↑, 1,  

Kinase & Signal Transduction

HCAR2↑, 1,  

Migration

CLDN1↑, 2,   MUC1↑, 1,   ZO-1↑, 2,  

Angiogenesis & Vasculature

NO↓, 1,  

Barriers & Transport

CLDN3↑, 1,   IBI↑, 1,   OCLN↑, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   HCAR2↑, 1,   IFN-γ↓, 1,   IL6↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   PGE2↓, 1,   TLR4↓, 1,  

Drug Metabolism & Resistance

eff↓, 1,  

Clinical Biomarkers

GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes

memory↑, 1,  
Total Targets: 26

Scientific Paper Hit Count for: CLDN1, claudin-1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:968  State#:%  Dir#:2
wNotes=on sortOrder:rid,rpid

 

Home Page